<DOC>
	<DOCNO>NCT00746499</DOCNO>
	<brief_summary>Healthy subject take study drug mouth twice day 7 consecutive day , blood cervicovaginal sample take morning around AM dose . Two visit , ~14 hrs length require Day 1 7 . The purpose study measure much raltegravir find genital tract take orally .</brief_summary>
	<brief_title>Pharmacokinetic Study Raltegravir Healthy Premenopausal Women .</brief_title>
	<detailed_description>This study look blood cervicovaginal fluid ( CVF ) sample healthy volunteer take raltegravir . The purpose study measure extent raltegravir penetrate body compartment , genital tract . Subjects take study drug 7 day , total 10 visit research center require . A screening visit occur 28 day On Days 1 7 subject stay research center approximately 12 hour schedule blood CVF sampling . Days 3-6 8-9 involve short visit research center one pre-dose blood CVF sample morning dose . A follow visit occur 7-10 day last dose .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy premenopausal female subject Between age 18 49 year With intact uterus cervix ( Healthy define irregular menstrual cycle clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Negative serum pregnancy test screen use least one method contraception Body Mass Index ( BMI ) approximately 18 30 kg/m^2 And total body weight &gt; 50 kg ( 110 lb )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>